Related Experiment Video

Updated: Jul 13, 2026

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

Gastrointestinal neuroendocrine tumors: a role for targeted therapies?

Matthew H Kulke1

  • 1Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Dana-Farber Cancer Institute, 44 Binney Street, Boston, Massachusetts 02115, USA. matthew_kulke@dfci.harvard.edu

Endocrine-Related Cancer
|July 20, 2007
PubMed

Insights

Traditional treatments offer limited benefit for advanced gastrointestinal neuroendocrine tumors. Novel targeted therapies, including those inhibiting vascular endothelial growth factor and mTOR, show promise for improved patient outcomes.

Area of Science:

  • Oncology
  • Gastroenterology
  • Medical Therapeutics

Background:

  • Advanced gastrointestinal neuroendocrine tumors (GI-NETs) present significant treatment challenges.
  • Traditional therapies like debulking, somatostatin analogs, interferon-alpha, and chemotherapy offer limited efficacy and potential toxicity.
  • There is a critical need for more effective treatment strategies for advanced GI-NETs.

Purpose of the Study:

  • To review the current landscape of treatment for advanced gastrointestinal neuroendocrine tumors.
  • To highlight the emerging role of novel targeted agents in managing advanced GI-NETs.
  • To discuss the potential of future therapeutic approaches based on ongoing research.

Main Methods:

  • Review of existing clinical studies and literature on gastrointestinal neuroendocrine tumor treatments.
  • Analysis of the efficacy and toxicity profiles of traditional and novel systemic agents.
  • Evaluation of ongoing clinical trials investigating targeted therapies.

Main Results:

  • Traditional therapies provide limited anti-tumor activity and benefit for advanced GI-NETs.
  • Somatostatin analogs effectively manage hormonal symptoms but rarely induce tumor regression.
  • Novel agents targeting vascular endothelial growth factor and mammalian target of rapamycin pathways show promising anti-tumor activity in early studies.

Conclusions:

  • Novel targeted therapies represent a promising advancement in the treatment of advanced gastrointestinal neuroendocrine tumors.
  • Ongoing clinical trials are crucial for defining the role of these agents in future treatment paradigms.
  • Further research is needed to optimize the use of targeted agents and improve patient outcomes.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...